Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice

Ann N Y Acad Sci. 2000:920:328-31. doi: 10.1111/j.1749-6632.2000.tb06943.x.

Authors

C A Lemere¹, R Maron, E T Spooner, T J Grenfell, C Mori, R Desai, W W Hancock, H L Weiner, D J Selkoe

Affiliation

¹ Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. lemere@cnd.bwh.harvard.edu

PMID: 11193172
DOI: 10.1111/j.1749-6632.2000.tb06943.x

No abstract available

MeSH terms

Administration, Intranasal
Alzheimer Disease / drug therapy*
Alzheimer Disease / genetics
Alzheimer Disease / pathology
Amyloid beta-Peptides / administration & dosage
Amyloid beta-Peptides / immunology*
Amyloid beta-Peptides / therapeutic use*
Amyloid beta-Protein Precursor / genetics*
Animals
Antibody Formation
Brain / pathology
Humans
Mice
Mice, Transgenic
Plaque, Amyloid / pathology

Substances

Amyloid beta-Peptides
Amyloid beta-Protein Precursor